Objective: This study was performed to investigate the difference in the serum-cholesterol-and triglyceridelowering activities between phytosterols dissolved in diacylglycerol (PSaDG) and dispersed in triacylglycerol (PSaTG). The effects of the solvent on the concentrations of serum b-sitosterol and campesterol were examined. Design: The study had a randomised crossover design. Subjects: Twelve healthy normocholesterolemic or moderately hypercholesterolemic men aged 29 ± 50 y participated in this study. Interventions: For 2 weeks before the test period (designated as the control period), all subjects consumed control mayonnaise (PS free) daily with supper and were randomly assigned to two groups for the 2 week test period; one group was given mayonnaise containing PS (500 mgaday) dissolved in DG (10 gaday), and the other mayonnaise containing PS (500 mgaday) dispersed in TG (10 gaday). After a wash out period consuming control PS-free mayonnaise for 4 weeks, the groups were reversed for 2 weeks. Results: PSaTG feeding had no effect on the serum cholesterol level. In contrast, PSaDG feeding signi®cantly reduced the total and LDL cholesterol levels from the initial value of 5.57 to 5.31 mmolal (4.7%; P`0.05) and from 3.69 to 3.39 mmolal (7.6%; P`0.05), respectively. Moreover, the degree of total cholesterol reduction induced by PSaDG feeding in the test period was signi®cantly greater than that induced by PSaTG feeding (P`0.05). In addition, the serum b-sitosterol and campesterol concentrations did not change during the PSaTG or PSaDG feeding periods. Conclusions: Dissolution of PS in DG had a better serum cholesterol lowering effect than dissolution in TG.
Introduction
Phytosterols (PS), abundant in the fat-soluble fractions of plants, are consumed at levels of 200 ± 400 mgaday in western diets (Jones et al, 1997) . PS have become ingredients of increasing importance in our diet since Peterson (1951) ®rst reported that the addition of soy sterols to a cholesterol-enriched diet prevented increases in plasma cholesterol level and signi®cantly reduced the incidence of atherosclerotic plaque in the chick aorta (Peterson et al, 1952) . Clinical investigations under a wide range of study conditions have shown that PS administration in human subjects reduces plasma total cholesterol and LDL cholesterol levels (Jones et al, 1997) . A number of theories have been advanced concerning the mechanism by which PS function as a serum cholesterol depressant. It is generally accepted that PS inhibit intestinal absorption of cholesterol (Ling & Jones, 1995; Jones et al, 1997) .
Although few side effects were reported in these clinical trials, relatively large amounts of PS (1.5 ± 3.0 gaday) have to be given to obtain signi®cant cholesterol-lowering effects (Heinemann et al, 1986; Vanhanen et al, 1993) . In addition, PS are hardly soluble in oil or water, and so they are usually administered in crystalline form (Sugano et al, 1976) . These drawbacks have limited the wider use of PS. Recently, Pelletier et al showed that 700 mg of PSaday mixed with butter fat lowered serum cholesterol in normocholesterolemic subjects (Pelletier et al, 1995) . In addition, Hendriks et al also reported that spread containing 830 mg of PS, mainly in esteri®ed form, had a cholesterol lowering effect in normocholesterolemic and mildly hypercholesterolemic subjects (Hendriks et al, 1999) . These reports demonstrated the ef®cacy of PS at low doses and further suggested the possibility of the wider use of PS.
On the other hand, we found that PS could be dissolved in dietary diacylglycerol (DG) at higher levels without esteri®cation. The actual solubility of PS in DG and triacylglycerol (TG) was 6.0 and 1.3%, respectively. Therefore, DG may be a useful oil for enhancing the cholesterol lowering effect of PS, since Ostlund et al clearly showed that solubilisation of PS in phospholipids improved the bioavailability despite a quite low dose (Ostlund et al, 1999) . DG is found naturally as a minor component in various vegetable oils and fats (D'Alonzo et al, 1982) . DG is currently used in small quantities in foods as an emulsi®er. Recent studies have suggested that DG consumed in larger amounts may have metabolic characteristics distinct from TG, which may produce bene®cial effects with regard to prevention and management of obesity. Experimental studies in animals and humans have shown that DG reduces postprandial triglyceridemia compared with TG control (Murata et al, 1994; Taguchi et al, 2000) . In controlled feeding studies, DG reduced body weight and abdominal fat stores in Japanese men .
In the present study, we investigated serum cholesterol and triglyceride changes caused by PS dissolved in DG compared with those in TG in humans.
Methods

Subjects and experimental design
Twelve normocholesterolemic or moderately hypercholesterolemic (serum total cholesterol: 4.66 ± 6.78 mmolal) healthy men aged 30 ± 50 y participated in this study (Table 1 ). All subjects gave their informed consent before the study. This study was performed in accordance with the declaration of Helsinki. The study was carried out according to a randomised crossover design. For 2 weeks before the test period (designated as the control period), all subjects consumed control mayonnaise daily with supper and were randomly assigned to two groups; one given mayonnaise containing PS dissolved in DG (PSaDG mayonnaise) and the other given mayonnaise containing PS dispersed in TG (PSaTG mayonnaise) daily with supper for a 2 week test period. After a wash-out period consuming control mayonnaise for 4 weeks, the groups were reversed for 2 weeks. The subjects were requested to maintain their normal lifestyle and dietary pattern. Each subject recorded a food diary during the study periods. Fat and energy contents in self-selected meals were calculated according to the Fourth Revision of the Standard Tables of Food Composition in Japan (The Ministry of Science and Technology, 1982) . Health status and medicine use were evaluated by a questionnaire at the end of each period. The medical investigator consulted the subjects when additional information was needed. This study was approved by the Ethics Committee of the Kao Corporation.
Materials and chemicals PS (47% b-sitosterol, 27% campesterol, 25% stigmasterol) were purchased from Henkel (Dusseldorf, Germany). PS was used without esteri®cation or hydrogenation. DG was prepared as reported previously (Murata et al, 1994) . Brie¯y, glycerol was esteri®ed with fatty acids from rapeseed oil by 1,3-speci®c lipase and puri®ed by silicic acid chromatography. Puri®ed DG to which had been added 5.0 wt% PS was used as dietary DG for experiments. TG containing 5.0 wt% PS was prepared as mixed oil with rapeseed, soybean and saf¯ower oil to make the fatty acid composition the same as that of DG. As shown in Table 2 , the fatty acid composition of DG was indistinguishable from that of TG. The majority of fatty acids in TG were present as TG, while the majority of fatty acids in DG were recovered mainly as 1,3-and to a lesser extent as 1,2-diacylglycerol (the 1,3-a1,2-ratio was 7X3; Nagao et al, 2000) . Packets containing 10 g portions of DG or TG mixed with the daily PS dose of 500 mg were prepared as PSaDG or PSaTG mayonnaise (test mayonnaise). Packets containing 10 g portions of TG without PS were prepared as control mayonnaise. PS did not affect the taste or smell of the mayonnaise. 
Serum lipid analysis
Overnight fasting blood samples were collected from each volunteer before breakfast at the beginning and the end of each period of the trial. Serum was obtained by centrifugation at 1500 g for 15 min at 4 C. Serum total cholesterol, HDL-cholesterol and triglyceride concentrations were determined by enzymatic methods using an Olympus AU600 automatic analyser (Olympus, Tokyo, Japan) at the clinical laboratory facility in Mitsubishi Kagaku BCL (Yokohama, Japan). Serum LDL-cholesterol was calculated according to Friedewald et al (1972) . Serum PS concentrations were determined by gas ± liquid chromatography from the nonsaponi®able material of serum lipid as reported previously (Jones et al, 1999; Ntanios & Jones, 1998) . Brie¯y, 0.5 ml serum samples were saponi®ed with 0.5 mol methanolic KOHaL for 1 h at 100 C and the nonsaponi®able materials were extracted with petroleum ether. 5a-Cholestane (Sigma, St Louis, MO) was used as an internal standard. The extract was dried and the residue was silylated (TMSI-H; GL Sciences Inc., Tokyo, Japan) for analysis by gas ± liquid chromatography. Samples were injected into a gas ± liquid chromatograph equipped with a¯ame ionisation detector (GC-17A Ver.3; Shimadzu, Kyoto, Japan) and with a 30 m capillary column (TC-5; GL Sciences Inc., Tokyo, Japan). Detector and injector temperatures were 310 and 300 C, respectively. PS peaks were identi®ed by comparison with authentic standards (Tama Biochemical Co. Ltd, Tokyo, Japan).
Statistical analysis
The statistical signi®cance of differences was tested determined using the two-tailed Student t-test and paired t-test and analysis of variance with repeated measurements. A P-value of less than 0.05 was considered statistically signi®cant.
Results
Dietary fat intake was similar when volunteers consumed
PSaDG mayonnaise (85.84 AE 12.2 gaday) and PSaTG mayonnaise (83.25 AE 14.2 gaday). Dietary energy intake was also not signi®cantly different between the periods of ingestion of PSaDG mayonnaise (9179.6 AE 1149.2 kJaday) and of PSaTG mayonnaise (9217.1 AE 1250.6 kJaday). No side effects were reported and all subjects con®rmed compliance with the study protocol. All mayonnaise was consumed by each volunteer every day. Table 3 shows the concentrations of serum total, LDLand HDL-cholesterol and triglyceride determined at the beginning and the end of each treatment. PSaTG feeding slightly reduced LDL-cholesterol levels from the initial value of 3.57 to 3.43 mmolal (not signi®cant), despite the lack of changes in the total cholesterol level. In contrast, PSaDG feeding signi®cantly reduced total and LDLcholesterol levels from the initial value of 5.57 to 5.31 mmolal (4.7%; P`0.05) and from 3.69 to 3.39 mmolal (7.6%; P`0.05), respectively. Moreover, the degree of total cholesterol reduction induced by PSaDG feeding in the test period was signi®cantly greater than that induced by PSaTG feeding (P`0.05). In the PSaTG feeding group, serum triglyceride level increased from the initial value of 1.65 to 1.83 mmolal, while in the PSaDG feeding group serum triglyceride level was slightly reduced from the initial value of 1.73 to 1.67 mmolal. However, this reduction was not statistically signi®cant. Table 4 shows the concentrations of serum b-sitosterol and campesterol determined at the beginning and the end of each treatment. Mean serum b-sitosterol and campesterol concentrations did not change during the study in either PSaDG or PSaTG feeding periods.
Discussion
The present study con®rmed signi®cant hypolipidemic activity of PSaDG superior to PSaTG over a short period (2 weeks) and with addition of small amounts of PS (500 mgaday) in a randomised crossover trial in normocholesterolemic and moderately hypercholesterolemic healthy volunteers (Table 3) . Ostlund et al reported that solubilisation of PS in phospholipids improves hypolipidemic activity even at fairly low doses (Ostlund et al, 1999) . 
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Therefore, the cholesterol-lowering activity of PSaDG was presumed to be due to the high solubility of PS in DG compared with TG.
When the serum cholesterol level was measured at 10-day intervals in subjects with primary hypercholesterolemia given a PS-enriched diet for 30 days, a time-dependent reduction in the plasma cholesterol level was observed (Jones et al, 1999) . Based on these results, administration of PSaDG for periods longer than 2 weeks was thought to further reduce the serum cholesterol levels. No signi®cant effects of dietary DG itself on the level of serum cholesterol have been reported in humans . Therefore, dietary DG appeared to augment the inhibitory effect of PS on the absorption of cholesterol in the intestine.
PS have been suggested to reduce serum cholesterol concentrations by competitively blocking cholesterol absorption from the intestinal lumen (Heinemann et al, 1986 (Heinemann et al, , 1993 , displacing cholesterol from bile salt micelles (Child & Kukis, 1986) , increasing bile salt excretion (Salen et al, 1970) , or hindering the cholesterol esteri®cation rate in the intestinal mucosa (Child & Kukis, 1983; Ikeda & Sugano, 1983) . Ikeda et al also showed that the only site of action was during binding of sterols to micelles (Ikeda et al, 1988) . As mentioned above, although many studies have been conducted, the precise mechanism of the inhibitory effect of PS on the absorption of cholesterol in the intestine is not fully understood.
In this study, it was not clear why the hypolipidemic activity of PSaDG was greater than that of PSaTG. One possibility is that the administration of PS in soluble form may be important for obtaining suf®cient contents in the micellar phase for the inhibition of cholesterol absorption (Vanhanen et al, 1993; Ostlund et al, 1999) . However, Mattson et al showed that b-sitosterol is more ef®cient than b-sitosterol esters in decreasing cholesterol absorption in humans (Mattson et al, 1982) . b-Sitosterol esters were reported to show better dissolution in dietary oils and to be hydrolysed to b-sitosterol during lipolysis of dietary fats (Miettinen & Siurala, 1971) . Also, no signi®cant increases in the hypocholesterolemic activity due to differences in solubility in oil were detected (Miettinen & Vanhanen, 1994) . These results implied that factors other than the solubility of PS in oil might be responsible for the competition of cholesterol for incorporation into mixed micelles in the intestine. Further detailed experiments are required to con®rm the mechanism of the hypolipidemic activity of PSaDG.
Serum b-sitosterol and campesterol concentrations did not change during the study in either the PSaDG or PSaTG feeding groups. Lees et al showed that the daily administration of 3 g of PS in hypercholesterolemic patients for 1 month failed to increase the plasma PS concentration (Lees et al, 1977) . Jones et al reported that even after daily administration of 1.7 g of PS to subjects with primary hypercholesterolemia for 1 month, the PS level was not signi®cantly different between the PS-fed and the control subjects (Jones et al, 1999) . In this study, each subject had a daily intake of 500 mg of PS. These results indicated that, even when PS are administered daily, the addition of small amounts of PS may not have a signi®cant effect on the serum PS level.
Previous clinical investigations showed that dietary rapeseed oil margarine rich in sitostanol ester was effective in lowering VLDL-and LDL-cholesterol and increasing HDL-cholesterol in hypercholesterolemic non-insulindependent diabetes mellitus (NIDDM) patients (Gylling & Miettinen, 1994) . These diseases are frequently associated with accelerated atherosclerosis and also hypertriglyceridemia. The purpose of the present study was to develop a PS preparation that could be used as a component of daily meals to lower cholesterol levels without requiring alterations in daily dietary habits. The results of the present study suggested that PS dissolved in DG has a better serumcholesterol-lowering effect than that in TG, and may be useful for treating hyperlipidemia.
